Chemical Works of Gedeon Richter PLC (BUD:RICHTER)

Ft 9650 0 (0%) Market Cap: 1.76 Til Enterprise Value: 1.70 Til PE Ratio: 6.06 PB Ratio: 1.56 GF Score: 77/100

Q3 2023 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Nov 08, 2023

Ft8890 (+1.89%)

Earnings
Q2 2023 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Aug 04, 2023

Ft8915 (-0.17%)

Earnings
Mithra Pharmaceuticals SA and Richter Gedeon Vegyeszeti Gyar Nyrt to Discuss Partnership for the Commercialisation of Donesta Presentation Transcript
Dec 20, 2022
Q4 2021 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Feb 28, 2022

Ft6965 (-1.62%)

Earnings
Q4 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Feb 07, 2020

Ft6760 (+1.81%)

Earnings
Q1 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
May 10, 2019

Ft5501.59 (-5.39%)

Earnings

Q4 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript

Feb 07, 2020 / 10:00AM GMT

Release Date Price: Ft6760 (+1.81%)

Transcript

Operator

Mr. Gabor Orban, CEO. Please go ahead, sir.

Gabor Orban

Gedeon Richter - CEO

Thank you very much. Good morning, everyone. Thank you for joining this call this morning. I'd like to begin by saying that I am very pleased with the significant progress that we achieved last year in shifting the composition of our sales turnover towards specialty products and key specialty projects. And we are now at 50%-plus share of the specialty-related turnover out of total pharma sales, which I think is a good step in the right direction and an important step in executing our strategy.

Last year consolidated sales moved higher at the double digit rate, and also the pharma segment saw the top-line move up by more than 10%, 11.7.

The strong increase in wholesale and retail is not an imminent part of the business strategy. It has to do with primarily with the basis that given that our [houses] were closed down in 2018. So we have this technical effect pushing the figures higher. That said, the pharma sales went up as a consequence of business related core

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.